Breast Cancer
FDA Follow-Up: Utilizing Olaparib in Clinical Practice for BRCA+ High Risk Early Breast Cancer
March 24, 2022
Article
Oncology Nursing News® speaks with the Charles E. Geyer, MD, FACP, an investigator with the phase 3 OlympiA trial to better understand the significance of olaparib’s approval and to determine what oncology nurses need to know about the new agent.
Olaparib Improves Survival in BRCA+, High-Risk Early Breast Cancer
March 23, 2022
Article
The PARP inhibitor demonstrated impressive overall survival benefit in patients with BRCA-mutated, HER2-negative, high-risk early breast cancer.
Checkpoint Inhibitors Present Unique Adverse Events, Require Careful Management Strategies in Breast Cancer
March 20, 2022
Article
La-Urshala Brock, FNP-BC, CNM, RNFA, discusses effective toxicity management for patients with breast cancer receiving pembrolizumab.
Bioimpedance Spectroscopy: How It Functions and How It Improves Subclinical Lymphedema Detection
March 15, 2022
Video
Sheila L. Ridner, PhD, RN, FAAN, provides an overview of bioimpedance spectroscopy and how the simple design allows for standardized subclinical lymphedema surveillance in breast cancer survivors.
Expert Discusses Best Practices for Managing Breast Cancer–Related Toxicities
March 14, 2022
Article
Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.
FDA Greenlights Olaparib for BRCA-Mutated, HER2-Negative Breast Cancer
March 14, 2022
Article
Olaparib is now FDA approved for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer and who have already undergone chemotherapy before or after surgery.
Ribociclib Regimen Elicits Longest Reported Median OS in HR+ Breast Cancer
March 13, 2022
Article
New data support the use of ribociclib plus letrozole in the treatment of patients with postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.
Cyropreservation Continues to Improve Fertility Options for Patients with Breast Cancer
March 12, 2022
Video
Lindsay Kroener, MD, offers an overview of current fertility preservation options for patients about to undergo cancer therapy.
Sacituzumab Govitecan Bests Chemotherapy by Improving Progression-Free Survival in HR+ Metastatic Breast Cancer
March 11, 2022
Article
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer achieved statistically significantly improvements in progression-free survival after receiving sacituzumab govitecan.
Real-World Data Confirm Talazoparib Clinical Benefit in HER2-Negative, Advanced Breast Cancer
March 10, 2022
Article
Patients with HER2-negative, locally advanced or metastatic breast cancer have experienced improved survival rates both in real-world data and the phase 3 EMBRACA trial.